$0.04
+0.02 (+117.19%)
Open$0.02
Previous Close$0.02
Day High$0.06
Day Low$0.02
52W High$53,451.36
52W Low—
Volume—
Avg Volume1.13B
Market Cap8.2K
P/E Ratio—
EPS$-205,055.95
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+32,274.1% upside
Current
$0.04
$0.04
Target
$13.50
$13.50
$9.80
$13.50 avg
$19.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.18B | 10.47B | 180.5K |
| Net Income | -2,873,510,358,333 | -2,421,497,492,977 | -19,611 |
| Profit Margin | -25,708.3% | -24,422.8% | -10.9% |
| EBITDA | -2,290,571,274,425 | -2,037,493,174,816 | -25,362 |
| Free Cash Flow | — | — | -13,693 |
| Rev Growth | +6.8% | +6.8% | +10.1% |
| Debt/Equity | 0.65 | 0.65 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |